Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery

Pharmaceutical Research

Volumn 29, Issue 1, 2012, Pages 83-96

  Yu, An ^a   Pang, Zhiqing ^b,c   Lu, Wei ^b,c   Yin, Qi ^b,c   Gao, Huile ^b,c   Jiang, Xinguo ^b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c School of Pharmacy   (China)

Author keywords

BBB; Brain delivery; Lactoferrin; Peptide; Polymersomes

Indexed keywords

6 COUMARIN; AMYLOID BETA PROTEIN[25-35]; CASPASE 3; CD68 ANTIGEN; CHOLINE ACETYLTRANSFERASE; FLUORESCENT DYE; HUMANIN; LACTOFERRIN CONJUGATED MACROGOL POLYGLACTIN POLYMERSOME; POLYMER; PROTEIN BAX; S14G HUMANIN; UNCLASSIFIED DRUG; COUMARIN 6; COUMARIN DERIVATIVE; DRUG CARRIER; GLY(14) HUMANIN, MICE; GLY(14)-HUMANIN, MICE; LACTIC ACID; LACTOFERRIN; LIPOSOME; MACROGOL DERIVATIVE; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; BLOOD BRAIN BARRIER; BRAIN DRUG DELIVERY SYSTEM; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; RAT; ROENTGEN SPECTROSCOPY; SURFACE PROPERTY; ZETA POTENTIAL; ALZHEIMER DISEASE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CRYOELECTRON MICROSCOPY; DRUG EFFECT; MALE; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; CASPASE 3; COUMARINS; CRYOELECTRON MICROSCOPY; DRUG CARRIERS; LACTIC ACID; LACTOFERRIN; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84860369451     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0513-7     Document Type: Article

References (42)

1. Huynh GH, Deen DF, Szoka Jr FC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release. 2006;110:236-59. (Pubitemid 41827478)
2. Cornford EM, Cornford ME. New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol. 2002;1:306-15. (Pubitemid 37159174)
3. Pardridge WM. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. International Congress Series. 2005;1277:49-62. (Pubitemid 44262151)
4. Smith QR. Carrier-mediated transport to enhance drug delivery to brain. International Congress Series. 2005;1277:63-74. (Pubitemid 43693331)
5. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. PNAS. 2007;104:7594-9. (Pubitemid 47185951)
6. Witt KA, Davis TP. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J. 2006;8:76-88.
7. Visser CC, Voorwinden H, Crommelin DJA, Danhof M, Boer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res. 2004;21:761-9. (Pubitemid 39011297)
8. Sarzehi S, Chamani J. Investigation on the interaction between tamoxifen and human holo-transferrin: determination of the binding mechanism by fluorescence quenching, resonance light scattering and circular dichroism methods. Int J Biol Macromol. 2010;47:558-69.
9. Chamani J, Vahedian-Movahed H, Saberi MR. Lomefloxacin promotes the interaction between human serum albumin and transferrin: a mechanistic insight into the emergence of the antibiotic's side effects. J Pharm Biomed Anal. 2011;55:114-24.
10. Boado RJ, Zhang YF, Zhang Y, Pardridge WM. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96:381-91. (Pubitemid 46232272)
11. Suzuki YA, Lopez V, Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005;22:2560-75. (Pubitemid 41721230)
12. Ji B, Maeda J, Makoto H, Higuchi M, Inoue K, Akita H, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci. 2006;78:851-5. (Pubitemid 43082309)
13. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007;32:1054-82. (Pubitemid 47198293)
14. Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009;88:272-85.
15. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol. 2006;6:494-500. (Pubitemid 44348531)
16. Discher DE, Eisenberg A. Polymer vesicles. Science. 2002;297:967-73. (Pubitemid 34856022)
17. Meng FH, Engbers HMG, Feigen J. Biodegradable polymer vesicles as a basis for artificial cells: encapsulation, release and targeting. J Control Release. 2005;101:187-98.
18. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCl: hydrolysis triggered controlled release vesicles. J Control Release. 2004;96:37-53. (Pubitemid 38438488)
19. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymer vesicles loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release. 2006;116:150-8. (Pubitemid 44868999)
20. Mamiya T, Ukai M. [Gly14]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol. 2001;134:1597-9. (Pubitemid 34038091)
21. Avgoustakis K. Pegylated poly(Lactide) and poly(Lactide-Co-Glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1:321-33.
22. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release. 2004;96:449-61. (Pubitemid 38553923)
23. Choucair A, Soo PL, Eisenberg A. Active loading and tunable release of doxorubicin from block copolymer vesicles. Langmuir. 2005;21:9308-13. (Pubitemid 41433979)
24. Wu J, Eisenberg A. Proton diffusion across membranes of vesicles of poly(styrene-b-acrylic Acid) diblock copolymers. JACS. 2006;128:2880-4.
25. Huwyler J, Wu DF, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. PNAS. 1996;93:14164-9. (Pubitemid 26424263)
26. Lu W, Wan J, She ZJ, Jiang XG. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release. 2007;118:38-53. (Pubitemid 46283096)
27. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002;19:1137-43. (Pubitemid 34984997)
28. Taylor S, Brock J, Kruger C. Safety determination for the use of bovine milkderived lactoferrin as a component of an antimicrobial beef carcass spray. Regul Toxicol Pharm. 2004;39:12-24. (Pubitemid 38121301)
29. Shard AG, Davies MC, Li YX, Volland C, Kissel T. XPS and SSIMS analysis revealing surface segregation and short-range order in solid films of block copolymers of PEO and PLGA. Macromolecules. 1997;30:3051-7. (Pubitemid 127579446)
30. Novotná K, Havliš J, Havel J. Optimisation of high performance liquid chromatography separation of neuroprotective peptides: fractional experimental designs combined with artificial neural networks. J Chromatogr A. 2005;1096:50-7. (Pubitemid 41653123)
31. Thom SR, Bhopale VM, Fisher D, Zhang J, Gimotty P. Delayed neuropathology after carbon monoxide poisoning is immune-mediated. Proc Natl Acad Sci. 2004;101:13660-5. (Pubitemid 39238459)
32. Alric L, Orfila C, Carrere N, Beraud M, Carrera G, Lepert JC, et al. Reactive oxygen intermediates and eicosanoid production by kupffer cells and infiltrated macrophages in acute and chronic liver injury induced in rats by CCl4. Inflamm Res. 2000;49:700-7. (Pubitemid 32097086)
33. 25-35 induced memory impairment in mice. Neuropharmacology. 2008;55:639-47.
34. Tajima H, Kawasumi M, Chiba T, Yamada M, Yamashita K, Nawa M, et al. A humanin derivative, S14G-HN, prevents amyloid-induced memory impairment in mice. J Neurosci Res. 2005;79:714-23. (Pubitemid 40476451)
35. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol. 2006;6:494-500. (Pubitemid 44348531)
36. Pang ZQ, Lu W, Gao HL, Hu KL, Chen J, Zhang CL, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release. 2008;128:120-7.
37. Nittaa A, Itoha A, Hasegawaa T, Nabeshima T. β-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett. 1994;170:63-6.
38. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropath Exp Neur. 1997;56:86-93. (Pubitemid 127470330)
39. MacGibbon GA, Lawlor PA, Sirimanne ES, Walton MR, Connor B, Young D, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res. 1997;750:223-34. (Pubitemid 27116267)
40. Grossoa CA, Tamb J, Royb S, Xanthoudakisb S, Costaa DD, Nicholsonb DW, et al. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease. Neuroscience. 2006;141:863-74.
41. Guo B, Zhai DY, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423:456-61. (Pubitemid 36626999)
42. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-5.